Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Jolly Mazumdar"'
Autor:
Anne-Marie Martin, Jeffrey Legos, Vicki Goodman, Jennifer Carver, Anne O'Hagan, Patricia Haney, Patrick Hwu, Axel Hauschild, Richard Kefford, Keith Flaherty, Dirk Schadendorf, Georgina V. Long, Michelle Casey, Jolly Mazumdar, Robert Gagnon, Ademi Santiago-Walker
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) tramet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4d3d38da62573352abaa7748422d3c
https://doi.org/10.1158/1078-0432.c.6524792.v1
https://doi.org/10.1158/1078-0432.c.6524792.v1
Autor:
Anne-Marie Martin, Jeffrey Legos, Vicki Goodman, Jennifer Carver, Anne O'Hagan, Patricia Haney, Patrick Hwu, Axel Hauschild, Richard Kefford, Keith Flaherty, Dirk Schadendorf, Georgina V. Long, Michelle Casey, Jolly Mazumdar, Robert Gagnon, Ademi Santiago-Walker
Supplementary Figure S1. Distribution of BRAF V600E cfDNA mutation fraction across study samples; Supplementary Figure S2. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f3ce7b899723d4e09fb698884ab6a5e
https://doi.org/10.1158/1078-0432.22461464
https://doi.org/10.1158/1078-0432.22461464
Autor:
Anne-Marie Martin, Jeffrey Legos, Vicki Goodman, Jennifer Carver, Anne O'Hagan, Patricia Haney, Patrick Hwu, Axel Hauschild, Richard Kefford, Keith Flaherty, Dirk Schadendorf, Georgina V. Long, Michelle Casey, Jolly Mazumdar, Robert Gagnon, Ademi Santiago-Walker
Supplementary Figure S1. Distribution of BRAF V600E cfDNA mutation fraction across study samples; Supplementary Figure S2. cfDNA-ND patients exhibited higher response rates to dabrafenib and trametinib compared with cfDNA V600E/K patients; Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67497579b822a676faffaa50ba0c91b5
https://doi.org/10.1158/1078-0432.22461467.v1
https://doi.org/10.1158/1078-0432.22461467.v1
Autor:
Hendrik-Tobias Arkenau, Li Yan, Jolly Mazumdar, Noelia Nebot, K. Auger, Jianping Zhang, Ruth Plummer, Sarah P. Blagden, Alastair Greystoke, Jean-Charles Soria, Jerry M. Tolson, Ivana Rizzuto, Debra Rogan, Gabriel Mak, Ronald A. Fleming, Anas Gazzah
Publikováno v:
British Journal of Cancer
Background Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. Methods This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib
Autor:
Patricia Haney, Michelle Casey, Keith T. Flaherty, Anne O'Hagan, Ademi Santiago-Walker, Dirk Schadendorf, Vicki L. Goodman, Axel Hauschild, Jeffrey J. Legos, Richard F. Kefford, Robert C. Gagnon, Patrick Hwu, Jolly Mazumdar, Anne-Marie Martin, Georgina V. Long, Jennifer Carver
Publikováno v:
Clinical Cancer Research. 22:567-574
Purpose: Tumor-derived circulating cell–free DNA (cfDNA) is a potential alternative source from which to derive tumor mutation status. cfDNA data from four clinical studies of the BRAF inhibitor (BRAFi) dabrafenib or the MEK inhibitor (MEKi) tramet
Publikováno v:
Journal of Cellular and Molecular Medicine
• Introduction • From metabolic adaptation to stem cell signalling • HIF-1α regulates Notch effects on cellular differentiation • Stem cell pluripotency requires HIF target gene function • O2 regulation of Wnt signalling is differentiation
Autor:
Todd M. Bauer, Catherine E. Ellis, Michele Maio, Helen Zhou, Patrick A. Mayes, Sapna Yadavilli, Aaron R. Hansen, Eric Angevin, Hui K Gan, Michael Millward, Juan Martin-Liberal, Axel Hoos, Jessica Katz, Jolly Mazumdar, Jan H.M. Schellens, Roxanne C. Jewell, Danny Rischin, Rigel Hall
Publikováno v:
Cancer Research. 77:CT039-CT039
Background Inducible T cell Co-Stimulator (ICOS), a member of the CD28/B7/CTLA immunoglobulin receptor superfamily, is expressed on T cells after engagement with cognate antigen and activation. ICOS provides a co-stimulatory signal augmenting T cell
Autor:
Peter M. Voorhees, Paul G. Richardson, Adam D. Cohen, Catherine Wang, Jolly Mazumdar, Zangdong He, Larry D. Anderson, Catherine E. Ellis, Joanna Opalinska, Rakesh Popat, Heather J. Sutherland, Nikoletta Lendvai, Stephen DeWall, Ed N. Libby, Suzanne Trudel
Publikováno v:
Blood. 128:1148-1148
Background Expression of BCMA, a cell surface receptor in the TNF superfamily, is restricted to B cells at later stages of differentiation and is requisite for the survival of long lived plasma cells. BCMA is expressed on MM cells at variable levels.
Autor:
Randall S. Johnson, Jolly Mazumdar, Peter S. Klein, Joseph C. LaManna, Juan C. Chavez, M. Celeste Simon, W. Timothy O'Brien
Stem cells reside in specialized microenvironments or 'niches' that regulate their function. In vitro studies using hypoxic culture conditions (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea025bf151072a96ef28a738ce71328b
https://europepmc.org/articles/PMC3144143/
https://europepmc.org/articles/PMC3144143/
Autor:
M. Celeste Simon, Tyler Jacks, Alejandro Sweet-Cordero, Brian Keith, Amy C. Durham, Jolly Mazumdar, Joseph L. Kissil, Dhruv K. Pant, Lewis A. Chodosh, Michele M. Hickey, Anil Vachani
Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. The oxygen-sensitive hypoxia inducible factor (HIF) transcriptional regulators HIF-1α and HIF-2α are overexpressed in many human NSCLCs, and constitutive HIF-2α ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d58b1d002fa7e0cbd7f696571318a1
https://europepmc.org/articles/PMC2922515/
https://europepmc.org/articles/PMC2922515/